Pre-exposure prophylaxis (PrEP) clinical trial results using antiretrovirals can seem confusing, if not conflicting. We review recent antiretroviral pharmacokinetic studies to help explain PrEP trial results.
INTRODUCTION
We review key, recent clinical pharmacology studies to aid interpretation of completed pre-exposure prophylaxis (PrEP) randomized clinical trials (RCTs) using antiretroviral (ARV) drugs. The goal is to establish concentration-response between and within studies to identify effective target drug concentrations and other influential variables, like adherence, that affect PrEP efficacy. Target concentrations, once established, guide dose optimization and development of ARVs in the PrEP pipeline.
SELECTION OF ANTIRETROVIRALS FOR PRE-EXPOSURE PROPHYLAXIS
Since 2002, numerous vaginal microbicides for PrEP contained luminally active agents -detergent, polyanionic, or pH buffering mechanisms of action -which did not contain ARVs. These were selected for study, in part, to avoid resistance to treatment ARVs, limit systemic toxicity possible with oral drugs, and achieve high local concentrations at the putative mucosal site of action. As these non-ARV formulations failed to prevent HIV infection, treatment-proven tenofovir (TFV) was studied in a vaginal gel formulation and in its licensed oral formulations, tenofovir disoproxil fumarate (TDF) alone (Viread) and coformulated with emtricitabine (Truvada) [1] [2] [3] [4] [5] [6] . Extensive pharmacokinetic, safety, and antiviral data established for treatment accelerated development of TFV-containing oral and topical formulations for PrEP. Applying these drugs to sexual HIV prevention, however, required additional data to guide rational dosing and formulation development, especially for topical application, to understand the complex interactions of many influential drug and HIV-related variables ( Fig. 1) , including vaginal and rectal tissue pharmacokinetics, mucosal tissue toxicity (which might reduce adherence if symptomatic or increase HIV susceptibility), and luminal distribution of HIV within the female genital tract and colon to assure adequate distribution of ARVs in development [7] .
Tenofovir and emtricitabine (FTC) remain the only ARVs proven efficacious in clinical PrEP trials. TFV, an adenine nucleoside analog reverse transcriptase inhibitor, is a component of first-line highly active ARV therapy (HAART). TFV is a phosphonate, which requires only two phosphorylation steps by human nucleoside kinases to form the active moiety, tenofovir diphosphate (TFV-DP), which remains in the cell with an extended 150-180 h half-life in peripheral blood mononuclear cells (PBMCs) of HIV patients, far longer than the 17 h plasma half-life of the parent drug [8] [9] [10] [11] . The oral formulation, TDF, is an esterified prodrug with increased bioavailability compared with TFV. FTC is a cytidine nucleoside analog reverse transcriptase inhibitor which, compared with TFV, has a shorter half-life of both parent drug in plasma and the active intracellular anabolite, emtricitabine triphosphate, 8-10 h and 39 (range 29-56) h, respectively [12, 13] .
Pharmacology of oral and topical preexposure prophylaxis
Pharmacokinetics-focused studies describe the concentration-time course of TFV and FTC in diverse anatomic sites relevant to HIV protection.
HIV distribution after intercourse
Identification of the viral target in space and time enables optimization of PrEP ARV formulation and dosing to assure that the ARV outdistances and outlasts the virus at the site of infection. Over a decade ago, murine and primate models of retrovirus infection indicated that virus passes from vaginal lumen to mucosal tissue rapidly within 1 h and infects T cells in genital mucosa and regional lymph nodes, both directly and indirectly via dendritic cells, within 24 h [14] [15] [16] . Recently, Louissaint et al. [17 & ] described the distribution of cell-free and cell-associated HIV surrogates (virus-sized particles and autologous white blood cells) in the colon and KEY POINTS Small, intensive clinical pharmacology studies improve our ability to interpret outcomes in pre-exposure prophylaxis (PrEP) trials.
Increasing tenofovir concentration is associated with increasing HIV protection both within and among oral PrEP trials.
Adherence is responsible for most of the concentration variation in oral PrEP studies.
High rectal-to-vaginal ratios of active tenofovir diphosphate after oral dosing make it risky to generalize men who have sex with men (MSM) PrEP concentration targets to other at-risk populations.
Because tenofovir dosing in the vagina and rectum achieves local active drug tissue concentrations greater than 100 times concentrations achieved with oral dosing, far greater than could be explained by adherence differences, other influential variables must be imputed to explain poor outcomes in topical studies. ]. In both colon and vagina, the cell-free and cell-associated surrogates shared a largely coincident luminal distribution. Taken together, these animal and human studies indicate that optimal PrEP drugs, whether oral or topical, deliver HIV-inhibiting ARV concentrations to the peri-cervical region or into the recto-sigmoid prior to and for at least 24 h following sex. ] enable description of the luminal distribution and clearance of rectal microbicide formulations using noninvasive single photon emission computed tomography (SPECT). In feasibility studies, a rectal gel achieved the greatest accumulation in the recto-sigmoid colon, similar to the HIV surrogate studies above, with the maximal extent of distribution into the sigmoid and even the descending colon in a small subset of individuals. Gel migrated retrograde with time and was visible within the colon throughout 24 h. These methods are being used to optimize development of rectal microbicides. ]. This indicated similar pharmacokinetics, but large adherence differences.
Pharmacodynamics

Luminal drug distribution
Mucosal tissue distribution and clearance of antiretrovirals
In concentration ratio at 24 h that did not persist at 2 weeks. Because these were paired biopsies in the same women, the colon-to-vaginal ratio cannot be attributed to sex differences. However, when the investigators looked at TFV-DP concentrations in the highly relevant CD4 þ T cells extracted from tissue, the rectal-to-vaginal TFV-DP ratio was only 20-fold. In addition, they demonstrated a complex biphasic PBMC TFV-DP peak -first peak at 8-16 h, second peak at 96 h -before beginning terminal elimination with a 48 h PBMC half-life, similar to the plasma TFV gamma decay estimate, and a longer 112 h half-life in CD4 þ T cells. This complex early biphasic peak and delayed time to terminal decay may partly explain the shorter PBMC TFV-DP halflife estimates compared with the 150-180-h estimates in studies of HIV patients [9] [10] [11] . The half-lives in homogenates and unselected cells extracted from vaginal and rectal tissue were similar to PBMCs with CD4 þ cell half-lives typically longer. A second six-woman, single oral TDF dose study by Chen et al. [28 & ] replicated this complex biphasic TFV-DP pattern between days 1 and 3 before a terminal elimination half-life of 64 and 100 h in PBMC and CD4 þ cells, respectively.
Other ARVs with potential benefits over TDF/FTC are in earlier phases of PrEP development. CCR5 inhibitor, maraviroc, does not have other in-class drugs to raise resistance concerns, demonstrates greater vaginal (2-fold) and rectal (26-fold) tissue homogenate concentrations when compared with blood plasma after oral dosing, and cervico-vaginal fluid concentrations exceeded plasma concentrations 3 days after dosing [29, 30] . However, given poor adherence in some PrEP RCTs, a 16-h plasma maraviroc half-life, far shorter than TFV-DP, may be a liability if similarly brief in tissue. The 50-h plasma half-life of rilpivirine, a licensed oral non-nucleoside reverse transcriptase inhibitor, is far longer than maraviroc and lacks the initial phosphorylation delay seen with TFV-DP and FTC-TP -characteristics which may have advantages if its tissue distribution and clearance are favorable [31] . Directly attacking the adherence issue, an injectable rilpivirine formulation sustains blood, vaginal tissue, and rectal tissue concentrations in men and women for 28 days [32] . Also addressing adherence, a monthly vaginal ring containing dapivirine, an experimental nonnucleoside reverse transcriptase inhibitor, is being studied in two RCTs scheduled for completion in 2015. Importantly, rilpivirine and dapivirine have potential for within-class cross-resistance.
Pharmacokinetic data inform randomized clinical trials
Sparse pharmacokinetic data embedded in PrEP RCTs, especially when linked to smaller bridging pharmacokinetic studies, enhance understanding of concentration-response and modifying factors essential for dose selection and future trial design.
Within-study concentration-response
Several PrEP RCTs included pharmacokinetic data which provide evidence of concentration-response (Table 1) . Centre for the AIDS Programme of Research in South Africa (CAPRISA) 004 showed a decrease in HIV incidence with cervico-vaginal fluid TFV concentrations higher than 1000 ng/ml [33] .
In the iativa Profilaxis PreExposicion (iPrEx) study, presence of TFV and FTC moieties in blood plasma and in PBMCs was associated with 92% relative risk reduction compared with only 42% in all participants randomized to drug [34] . Partners PrEP reported a smaller bump in relative risk reduction in both TDF and TDF/FTC arms rising to 86 and 90%, respectively, when TFV was detected [using a more sensitive assay than in the iPrEx study] [35 && ]. In the Centers for Disease Control and Prevention (CDC) TDF2 study, TFV and FTC were more commonly detected in nonseroconverters (80 and 81%, respectively), compared with seroconverters (50%) for both drugs [36 && ]. In FEM-PrEP, concentrations at the beginning and end of the seroconversion window appeared to be less frequently detectible in seroconverters (15%) compared with nonseroconverting participants at similar time intervals (26%), but these were not statistically significant [37 && ].
Among-study concentration-response in oral studies
The TFV plasma concentrations reported in completed oral PrEP RCTs indicates a concentrationresponse among these studies (Fig. 2) , with the exception of iPrEx, which has a unique risk population [34,35 && -37 && ,38] . TFV concentration data contain substantial heterogeneity due, most likely, to variability between individuals and in time of unobserved prior doses. Similarly, confidence intervals of relative risk reduction are also large in some studies due to few seroconversions or small sample size.
iPrEx is the outlier among oral studies with median detectible ARV concentrations around 10 ng/ml, not much different from FEM-PrEP; yet, iPrEx had a 42% relative risk reduction compared with none [34,37 && ]. As receptive anal intercourse is the primary HIV risk for the men who have sex with men (MSM) in iPrEx, two adjustments are warranted. First, several oral dose pharmacokinetic studies indicate active drug TFV-DP concentrations As plasma TFV, not rectal tissue, is measured in RCTs, this colon-tovaginal ratio effectively shifts the 'effective' iPrEx plasma concentration rightward along the concentration axis. There is a second countering leftward shift in 'effective' TFV concentration due to increased risk of HIV infection via receptive anal intercourse in iPrEx compared with vaginal or penile exposures, which are the dominant risks in the other oral studies. The magnitude of site of infection and anatomic variation in active drug tissue concentration effects are too imprecise to make specific adjustments, but these factors may combine to bring iPrEx more closely in line with the concentration-response seen among the other studies.
Adherence influential in oral studies
The variation in concentration among RCTs far exceeds variability attributable to either interindividual variability in prior pharmacokinetic studies or prescribed daily dosing time in the day prior to clinic blood sampling. Comparison of geographic sub-populations in MTN-001 found five-fold differences in predose serum TFV concentration. As predose concentration is influenced by timing of the prior unobserved dose and individual pharmacokinetic variation, which was not seen following observed doses, we attribute most of these concentration differences to adherence.
Factors mitigating beneficial antiretroviral effect in topical studies
As tissue concentrations with topical dosing exceed those after oral dosing by more than 100fold, one would anticipate topical dose studies to have the best HIV protection. Even assuming the low level of adherence seen in FEM-PrEP, expected tissue concentrations in CAPRISA 004, and MTN-003 [Vaginal and Oral Interventions to Control the Epidemic (VOICE)] gel arm would exceed Partner's PrEP vaginal tissue concentrations by 10-fold. Results to the contrary -only 39% relative risk reduction in CAPRISA 004 and none in VOICE TFV gel arm -we postulate an unexplained dose-related variable at work that reduces the efficacy of topical dose regimens. Excessively high local concentrations of drug or the gel delivery vehicle are potential candidates worthy of additional exploration. If these are at fault, a simple formulation change (dose reduction and/or gel modification) could transform topical TFV dosing into a highly effective PrEP method.
CONCLUSION
Small clinical pharmacology studies richly inform our interpretations of concentration-response in oral PrEP RCTs and indicate that differences in adherence and anatomic site of HIV risk are both powerful explanatory variables which can guide selection of alternative regimens to achieve target concentrations. The underperformance of topical PrEP studies cannot be explained by low adherence and may be due, in part, to some product-related factor mitigating the high level of protection expected based on the concentration-response seen in oral studies. Beyond simply informing interpretation of their trial outcomes, earlier completion of these clinical pharmacology studies should improve the drug development process for the next generation of PrEP agents.
